omalizumab + budesonide + formoterol

Omalizumab + budesonide + formoterol is a combination therapy used primarily for the treatment of moderate to severe allergic asthma. Omalizumab is a monoclonal antibody that binds to immunoglobulin E (IgE), preventing it from attaching to mast cells and basophils, thereby reducing allergic inflammation. Budesonide is an inhaled corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta-2 adrenergic agonist (LABA) that relaxes bronchial smooth muscle and improves airflow. This combination has demonstrated improved clinical efficacy in controlling asthma symptoms, enhancing pulmonary function, and improving immune function compared to standard therapies alone[1][3][4][6]. Omalizumab is typically administered via subcutaneous injection; budesonide/formoterol as an inhalation therapy.

Brand names

Symbicort